Brief: Daewoong Pharmaceutical Welcomes ITC Decision to Review Judge’s Initial Determination
22/09/2020 12:39
Sept 22 (Reuters) - Daewoong Pharma 069620.KS :
* DAEWOONG PHARMACEUTICAL - COMMENTS ON DECISION BY U.S. ITC
TO
COMPREHENSIVELY RECONSIDER A JUDGE'S INITIAL DETERMINATION IN
CASE
* DAEWOONG PHARMACEUTICAL - ITC HAS ANNOUNCED IT WILL
REVIEW
SEVERAL ISSUES AS REQUESTED BY DAEWOONG AND EVOLUS
Source text for Eikon: ID:nBw8WhFTwa
Further company coverage: 069620.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Daewoong Pharma
See all newsBrief: Daewoong Pharma Q2 Operating. Profit 77 Billion Won, Up 23% Y/Y
Brief: Daewoong Pharma Wins 92.6 Billion Won Order
Brief: Daewoong Pharma Q4 Operating Profit 45.5 Billion Won, Up 9% From Year Earlier
Brief: Daewoong Pharma Q2 Operating Profit 62.5 Billion Won, Up 26% From Year Earlier
Brief: Daewoong Pharma Q1 Operating Profit 42 Billion Won, Up 34.5% From Year Earlier